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Abstract:  10 
Myxomatous mitral valve disease (MMVD) is the single most important acquired cardiovascular 11 
disease of the dog. Much is known about the cellular changes and the contribution of activated 12 
myofibroblasts (valve interstitial cells (aVICs) to the valve extra-cellular matrix remodelling 13 
characteristic of the disease. However, little is known on how aVIC survival might contribute to 14 
disease pathogenesis. This study examined the temporal (disease severity-dependent) and spatial 15 
distribution of aVICs in MMVD valves, the expression of a range of apoptosis-related genes in 16 
cultured VICs from both normal (quiescent VIC (qVIC) and diseased (aVIC) valves, and the differential 17 
effects of doxorubicin treatment, as a trigger of apoptosis, on expression of the same genes. 18 
Activated myofibroblasts were identified in normal valves at the valve base only (the area closest to 19 
the annulus), and then became more numerous and apparent along the valve length as the disease 20 
progressed, with evidence of cell survival at the valve base. There were no significant differences in 21 
basal gene expression comparing qVICs and aVICs for CASP3, FAS, BID, BAX, BCL2, CASP8, DDIAS, 22 
XIAP and BIRC5. After doxorubicin treatment (2mM) for 8hrs there was significant difference 23 
(P<0.05) in the expression of BID, BCL2, DDIAS, and CASP8, but when assessed for interactions using 24 
a mixed model ANOVA only CASP8 was significantly different because of treatment (P<0.05). These 25 
data suggest aVIC survival in MMVD valves may be a consequence of heightened resistance of aVICs 26 
to apoptosis, but would require confirmation examining expression of the relevant proteins. 27 
progression. 28 
Key Words: Myxomatous mitral valve disease, valve interstitial cells, cell culture, activated 29 
myofibroblasts, apoptosis 30 
1. Introduction: 31 
Myxomatous mitral valve disease (MMVD) is the most common acquired cardiac disease of the dog 32 
and can lead to heart failure and death (Borgarelli and Haggstrom, 2010). The main feature of 33 
MMVD is destruction and disorganisation of the extracellular matrix (ECM), which is believed to be a 34 
consequence of valve interstitial cells in the valve stroma transitioning from a quiescent (qVIC) 35 
phenotype to activated myofibroblasts (aVIC; alpha smooth muscle actin positive (αSMA+)) 36 
(Aupperle and Disatian, 2012; Disatian et al., 2008; Hadian et al., 2007; Han et al., 2010; Han et al., 37 
2008). A cardinal feature of MMVD is the increased numbers of aVICs, which correlates with disease 38 
progression and severity (Han et al., 2008; Lu et al., 2016). Activated myofibroblasts have previously 39 
been described adjacent to the myxomatous areas, with increased numbers in the sub-endothelium, 40 
but their extent and distribution throughout the entire length of the valve as disease progresses has 41 
not been reported (Han et al., 2008; Han et al., 2013; Lu et al., 2016). While several mechanisms 42 
have been suggested to contribute to the pathogenesis of MMVD, aVIC survival, either as a 43 
consequence of heightened senescence or reduced apoptosis (interconnected and related 44 
mechanisms), might be a contributing factor in the development and progression of MMVD 45 
(Surachetpong et al., 2013).  46 
The activity of activated myofibroblasts in tissue repair is limited by the process of apoptosis (Hinz et 47 
al., 2007). When this does not occur persistent tissue remodelling can ensue resulting in tissue 48 
damage often typified by excessive fibrosis (Desmouliere et al., 1995; Linge et al., 2005). The survival 49 
of activated myofibroblasts as a driver of disease is of particular interest in myocardial infarction and 50 
hepatic, renal and lung fibrosis, because therapeutic interventions to control apoptosis and cell 51 
senescence could have major impact on the management of the these diseases, and by extension to 52 
the management of MMVD (Hinz et al., 2012; Kisseleva et al., 2012; Lagares et al., 2017). For 53 
example, the presence of activated myofibroblasts in histological samples of fibrotic myocardial 54 
infarcts, several years after a known initiating event, is seen as indirect evidence of survival of 55 
activated myofibroblasts (Willems et al., 1994).   56 
The potential role of apoptosis in canine MMVD has been previously examined (Surachetpong et al., 57 
2013). Increased pro-apoptotic BCL-2-associated protein (BAX) and decreased anti-apoptotic B-cell 58 
lymphoma 2 protein (BCL-2) expression, without changes in cleaved caspase 3 expression or TUNEL 59 
(Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labelling) 60 
staining of apoptotic bodies have been reported in canine MMVD valves (Surachetpong et al., 2013). 61 
While these data might suggest cells are in a primed pro-apoptotic state, it might also reflect the 62 
complex interaction of pro-apoptotic factors and inhibitors of apoptosis. There is also evidence of 63 
epigenetic control of apoptosis with reduced expression of miR-20a, miR-17 and miR-30d (pro-64 
apoptotic and anti-senescence) and increased expression of pro-senescent p21 in affected valves 65 
(Karimian et al., 2016; Yang et al., 2018).  Transcriptomic profiling of canine mitral valves has 66 
identified changes in a range of apoptosis associated genes, including members of the BCL family 67 
(BCL6B and 9), CASP4 and CASP8, DED (death effector domain), DAD1 (defender against apoptotic 68 
cell death), and various angiopoietin and pleiotrophin genes (Lu et al., 2015b). Transcriptomic 69 
profiling has also found increased expression of CDKN1A and CDKN2A, which encode for the proteins 70 
P21 and P16 respectively (Lu et al., 2015b). These cyclin-depended kinase inhibitors are important in 71 
the control of cell senescence, and may have a role alone, or in tandem with apoptotic mechanisms, 72 
in controlling activated myofibroblast survival in MMVD (Childs et al., 2014). 73 
The control of apoptosis is complex and consists of intrinsic (stressor-induced mitochondrial 74 
damage) and extrinsic (tumour necrosis factor family member death ligand-induced; TNF) pathways, 75 
and has been reviewed extensively. These pathways converge to activate the executioner caspases 76 
3, 6 and 7. The important proteins in the pathways include the caspases, FAS-ligand (CD95) and BH3 77 
interacting-domain death agonist (BID) (pro-apoptotic), BCL-2 family members (both pro- and anti-), 78 
X-linked inhibitor of apoptosis (XIAP) (anti-), inhibitor of apoptosis proteins (IAP) family members 79 
such as survivin (BIRC5, anti-), and FADD-like IL-1β-converting enzyme-inhibitory protein (c-FLIP) and 80 
DNA damage induced apoptosis suppressor protein (DDIAS) (anti-). The important BCL-2 family are 81 
regulated by several pathways, including growth factors affecting PI3K, ERK 1/2, JAK/STAT and NFκβ, 82 
and this may be important considering the potential role of TGFβ and 5-HT signalling in MMVD 83 
pathogenesis (Disatian et al., 2010; Disatian and Orton, 2009; Driesbaugh et al., 2018; Tan et al., 84 
2019).  85 
We hypothesised that there is survival of activated myofibroblasts in canine MMVD valves and that 86 
this, in part, can be explained by a defect in the activation and progression of apoptotic pathways. 87 
To investigate this hypothesis, we examined the spatial and temporal distribution of aVICs in mitral 88 
valves to confirm survival, and then examined the expression of apoptotic genes by qVIC and aVICs 89 
in cell culture, before and after stimulation with doxorubicin (Tan et al., 2019).   90 
2. Materials and Methods: 91 
2.1 Tissue samples 92 
Dogs were euthanased with an intravenous pentobarbitone over-dose with full owner consent and 93 
the study was approved by the R(D)SVS Veterinary Ethics in Research Committee. No dogs were 94 
euthanased for the purpose of the study. Dogs with severe MMVD were typically euthanased 95 
because of intractable heart failure, and normal, mild and moderately affected dogs for non-cardiac 96 
reasons. Valves were collected from a range of dog breeds of varying ages and were graded 97 
independently by two of the authors (C-CL & BMC) as normal, mild, moderate or severely affected 98 
using a modification of the Whitney system (Whitney, 1974). A selection of valves were then 99 
processed for immunostaining (n=4 per grade; combination of elderly Cavalier King Charles Spaniels, 100 
elderly mixed breed dogs and young adult mixed breed dogs and beagles) or for valve interstitial cell 101 
culture (n= 11; combination of mixed breed dogs and beagles). For tissue sectioning, valves were 102 
washed with PBS, immersed in 4% paraformaldehyde and fixed at 4oC for 36 hours, and then rinsed 103 
in PBS and stored in 70% ethanol at 4oC until required. Samples for sectioning were collected from 104 
the mid-point of the anterior leaflet of normal valves and the approximate same position from 105 
grossly obvious areas of pathology on the anterior leaflet of diseased valves. Samples were paraffin-106 
embedded and four consecutive 5µm thick sections were collected onto gelatin coated slides. 107 
2.2. Valve interstitial cell (VIC) culture 108 
Valve interstitial cells (MMVD n=6;  normal n=5) were collected for culture from excised valves using 109 
previously described methods, except the culture media (Dulbecco’s Modified Eagle Medium 110 
(DMEM); Life Technologies, U.S.A) contained 2% instead of standard 10% v/v FBS in order to 111 
preserve cell phenotype (Latif et al., 2015; Liu et al., 2015; Tan et al., 2019). Cells were seeded in T75 112 
culture flasks (ThermoScientific) in 15ml of DMEM, with FGF-2 only added at that point, and 113 
incubated at 37˚C in 5% CO2. Culture medium was changed every 2-3 days, and once confluence was 114 
reached the cells were harvested by trypsinization (TrypLE™ Express; Life Technologies). Cell pellets 115 
was either re-suspended in culture medium for continued culture, or prepared for storage at -150˚C. 116 
Cells were used no later than passage five.  117 
2.3. Indirect immunofluorescence Immunohistochemistry  118 
A standard protocol was used as previously described (Lu et al., 2016).For antigen retrieval, sections 119 
were heated in citrate buffer for 5 minutes at 120˚C. Slides were mounted in Sequenza cassettes 120 
(Thermo Scientific, Shandon Sequenza Immunostaining Cassettes) with 200 µm of 0.5% PBS-121 
Tween20. Permeabilization and non-specific-blocking of antigens were performed with 10% goat 122 
serum (diluted in 0.5% Tween 20) (Vector Laboratories Inc.) for 30 minutes at room temperature. 123 
Sections were then incubated for 60 minutes at room temperature with mouse monoclonal anti-124 
αSMA antibody at 1:400 dilution (Sigma; cat. no. A2547) washed with 0.5% PBS-Tween20 and 125 
incubated for 30 minutes at room temperature with a goat anti-mouse fluorescein-conjugated 126 
secondary antibody at 1:1000 dilution (Invitrogen; Alexafluor, cat. no. A10667). Slides were mounted 127 
in medium containing the nuclear counterstain DAPI (ProLong Gold Antifade Reagent, Invitrogen), 128 
viewed immediately andor stored at -20˚C. Images were collected using a light fluorescence 129 
microscopy (Leica-DMLB) and  tile-scanning was performed using a Zeiss LSM-710 confocal 130 
microscope. The images were then assessed qualitatively for cell density and cell distribution. 131 
2.4. Cell RNA extraction, quantification and quality assessment 132 
Cell lysis was performed using the QIAshredder homogenizer (QIAGEN, Germany) and RNA was 133 
extracted from frozen cell pellets using the QIAGEN RNeasy Mini Kit (QIAGEN) according to the 134 
manufacturer’s protocol. Quantification of RNA and contamination assessment was performed using 135 
the Nanodrop 1000 Spectrophotometer Version 3.7.1 (Thermo Fisher Scientific). Samples were then 136 
promptly stored at -70˚C for batch complementary DNA (cDNA) generation.  137 
2.5. Reverse transcription, primer design and real-time quantitative polymerase chain reaction 138 
(RT-qPCR) 139 
Reverse transcription of RNA to cDNA was performed using the Superscript III™ Reverse 140 
Transcriptase kit (Invitrogen). Two primer pairs for each of BCL-2, DDIAS, BID and FAS one primer 141 
pair for CASP8, CASP3, BIRC5, XIAP and BAX were designed using Primer3web version 4.1.0 software 142 
(Untergasser et al., 2012, Koressaar and Remm, 2007) based on canine sequences from the Ensembl 143 
database. Second primer sequences for each of CASP8, CASP3, BIRC5, XIAP and BAX have been 144 
previously reported (Del Puerto et al., 2010, Yamazaki et al., 2013, Meichner et al., 2016). Primers 145 
for ACTA2 (αSMA) and TAGLN (SM22α) had previously been designed and optimized (Markby 2018). 146 
Expression of these genes in normal and diseased VICs was analysed at baseline in order to validate 147 
cell phenotype, with high ACTA2 and TAGLN expression expected in diseased VICs, but not in healthy 148 
VICs. Primers for the three reference genes used (GAPDH, MRPS25, RPL32) had previously been 149 
validated (Liu et al., 2015). Primer sequences are shown in Table 1. 150 
The Takyon™ Low Rox SYBR® Mastermix dTTP Blue kit (Eurogentec, Belgium) was used to perform 151 
RT-qPCR in 96-well PCR plates (ThermoScientific). RT-qPCR was then performed using the Stratagene 152 
MxPro Mx3000P (Agilent Technologies, U.S.A.). 153 
2.6. Doxorubicin induction of apoptosis 154 
Time-course experiments were undertaken to establish optimal timing for detection of apoptosis. 155 
One each of a normal and diseased VIC culture (passage 4) were tested with a REM134 canine 156 
mammary carcinoma cell line (passage 43). Cells were grown for 48hrs at 37oC in 5%CO2 and treated 157 
with 2mM doxorubicin hydrochloride (Medac, GmbH, 2mg/ml) (Forterre et al., 2011). Cells were 158 
harvested at 0, 2, 4, 8, 16 and 24hrs and examined for expression of BCL-2, BAX, BIRC5, CASP3 and 159 
the reference genes GAPDH, MRPS25, RPL32. Based on these results, experiments were undertaken 160 
in all the VIC samples, harvesting at 0, 4, 8 and 24hrs and examined for the expression of BCL-2, BAX, 161 
BIRC5, CASP3, CASP8, DDIAS, BID, XIAP and FAS. 162 
2.7. Modified ethidium homodimer and acridine orange viability assay 163 
Because doxorubicin treatment was likely to cause cell necrosis, this assay was used to determine 164 
the number of live, apoptotic and necrotic cells. VICs from four dogs were prepared and treated with 165 
doxorubicin in 96 well plates. A solution of ethidium homodimer inn DMSO (EH) and acridine orange 166 
(AO) (Invitrogen), each at 100µg/ml, was prepared in PBS (Ribble et al., 2005). Well plates were 167 
centrifuged at 453g for 5 minutes and 8µl of the AO/EH solution added to the 100ml of culture 168 
media in each well, giving a final concentration of 14.8µg/ml. After 2 minutes cells were examined 169 
by fluorescent microscopy and three photo-micrograph obtained, 100 cells counted in each frame 170 
and the percentage of live, dead and apoptotic cells calculated. 171 
2.8. Statistical analysis 172 
Statistical analysis was performed using Minitab 17 Statistical Software and IBM SPSS Statistics 24. 173 
Normality was assessed visually and using the Anderson-Darling test. A 2-sample t-test (for 174 
parametric data) or a Mann-Whitney U test (for non-parametric data) was used to compare ΔCt 175 
values to investigate for differences in gene expression between normal and diseased VIC groups at 176 
baseline. A one-sample t-test was used to compare individual ΔCt values of diseased VICs with the 177 
group of normal VICs when investigating individual genotypes. A mixed model analysis of variance 178 
(ANOVA) was used to investigate changes in gene expression following induction of apoptosis. Delta 179 
Ct was considered the dependent variable, VIC type (healthy or diseased) and treatment status were 180 
considered fixed effects and dog ID was a random effect. Standardized residuals were analysed 181 
visually for normality and found to be adequate in all cases. Significant interactions were analysed 182 
using an independent t-test. A value of p<0.05 was considered significant. 183 
3. Results 184 
A clear change in the density and distribution of activated myofibroblasts was identified, with 185 
increasing number of αSMA+ cells as the disease progresses, and along the length of the leaflet from 186 
distal zone to base (Fig. 1). In normal leaflets, αSMA+ cells were identified as a single layer only in 187 
the basal zone with some extension into the mid zone, and only on the atrial side of the leaflet. In 188 
mild to moderately diseased valves, additional linear clusters of αSMA+ cells were found extending 189 
to the valve edge, again primarily towards the atrial side in the sub-endothelium, and with retention 190 
of positive staining in the basal zone as seen in the normal valves. There was further increase in 191 
αSMA+ cells in severely affected leaflets, with extension to the ventricular side and deeper within 192 
the myxomatous core. Again positive staining of the mid and basal zone was retained. 193 
To check for accuracy of cell phenotype expression of ACTA2 and TAGLN was measured in all cells 194 
and two diseased samples had reduced gene expression, and this was factored into the analyses.  195 
Cells continued to grow after doxorubicin treatment with qVICs and aVICs retaining their 196 
characteristic morphology, as did the number of dead cells which appeared rounded, shrunken and 197 
detached from the culture flask base (Fig. 2). EH/AO staining identified a decrease in the proportion 198 
of live cells and an increase in apoptotic and necrotic cells at 8hrs for both qVICs and aVICs, but an 199 
increased percentage of apoptotic cells was also seen in untreated samples at 8hrs (Fig. 3). Although 200 
there was a -1.05 (XIAP) to 2.43 (DDIAS) fold change difference comparing qVICs and aVICs, in 201 
baseline expression for the apoptotic-related genes examined, no differences achieved statistical 202 
significance (Table 2). With doxorubicin treatment of qVIC (n=5) and aVIC (n=6) samples at 8hrs, 203 
there was a statistically significant increase in pro-apoptotic BID and CASP8 and a decrease in anti-204 
apoptotic BCL2 and DDIAS compared to untreated controls (p<0.05) (Table 3 and Fig. 4). When 205 
assessed for interaction using the mixed-model ANOVA, only CASP8 was significantly decreased in 206 
the aVICs (p<0.05) (Table 3).  207 
Removing the two aVIC samples with low ACTA2 and TAGLN expression, significant differences in 208 
expression of BID, BCL2 and DDIAS were retained, but not for CASP8. Gene expression at 4hrs post-209 
treatment identified a significant decrease in pro-apoptotic FAS and CASP8 and anti-apoptotic BCL2 210 
and DDIAS in aVICs, and a decrease in CASP8 and DDIAS in qVICs (p<0.01), with interaction identified 211 
for BCL2 and DDIAS (p<0.05). While there was no overall effect of doxorubicin on CASP3 expression, 212 
there was a crossover interaction with the mixed-model ANOVA, which post hoc analysis identified 213 
as an increase in CASP3 at 4hrs in control aVICs (p<0.05). Untreated qVIC and aVIC controls also 214 
showed changes at 4hrs, including increased FAS and BID in both and increased DDIAS in diseased 215 
and BCL2 in normal VICs (p<0.05). Removing the two aVIC samples with low ACTA2 and TAGLN 216 
expression removed the interaction for BCL2 and DDIAs, with only the treatment having a continual 217 
significant effect. While untreated VICs continued to grow, by 24hrs the majority of cells in the 218 
doxorubicin treated qVIC and aVIC groups appeared necrotic.  219 
4. Discussion 220 
This study identified a temporal and spatial pattern of activated myofibroblasts in canine MMVD 221 
characterised by increasing numbers and widening distribution of activated cells as the disease 222 
progressed. While it cannot be stated with certainty that the αSMA+ cells in the valve base and mid-223 
zones seen across all grades of disease is due to survival, the consistency of the finding in all dogs 224 
examined would be highly supportive of this conclusion. This suggests cell survival typical of 225 
heightened cell senescence and/or reduced apoptosis is found in MMVD. The appearance of aVICs is 226 
a hallmark of MMVD, but has been presumed to be closely associated with myxomatous pathology 227 
as it develops (Disatian et al., 2008; Han et al., 2008; Lu et al., 2016). While this is likely to be the 228 
case, aVICs are first identified in the basal zone and remain there throughout the natural progression 229 
of the disease. The extent to which aVIC numbers and distribution is a combination of cell migration, 230 
proliferation or transformation of the resident qVIC population is unknown. Increased expression of 231 
Ki67 has been reported suggesting proliferation is involved, but endothelial-to-mesenchymal 232 
transition might also contribute to the aVIC population (Lu et al., 2015a; Lu et al., 2016). There are 233 
no reports of cells being recruited from the circulating fibrocyte pool in dogs, but CD34+ cells have 234 
been identified in human MMVD, suggesting this may be a source (Barth et al., 2005). Further 235 
studies for markers of apoptosis (and senescence) are now needed examining aVICs at all locations 236 
in valve tissue and at all disease time-points.  237 
Survival of activated myofibroblasts is well recognised in other diseases, and for some this results in 238 
continual pathological changes, while for others pathology is not progressive (Desmouliere et al., 239 
1995; Hinz et al., 2012; Linge et al., 2005; Willems et al., 1994).  Similarly, survival of aVICs, and their 240 
accumulation in the mitral valve is an important process in the development and progression of 241 
MMVD, and may represent a potential therapeutic target for disease management. 242 
Differential expression of pro- and anti-apoptotic genes was not identified in VICs from normal and 243 
disease valves.  However, with doxorubicin aVICs differentially expressed CASP8 suggesting that 244 
aVICs have some resistance to normal apoptosis. Caspase 8 is the final enzyme in the extrinsic 245 
apoptotic pathway activating the executioner caspases as well as linking to and activating the 246 
intrinsic apoptotic pathway. Inhibitors of caspase 8 activity include DDIAS, which promotes 247 
phosphorylation, ubiquitination and degradation of the caspase 8 enzyme, but DDIAS was also found 248 
to be decreased in doxorubicin treated VICs (Im et al., 2018). However, DDIAS acts post-249 
translationally to control caspase 8 expression and so would not have an effect on the level of gene 250 
expression, but only on protein quantity and activity. An additional pro-survival mechanism for aVICs 251 
might be increased expression of BIRC5, which was found increased in the sub-analysis, although this 252 
did not achieve significance. BIRC5 encodes for the protein survivin, which inhibits the final steps of 253 
the apoptotic pathway, aiding XIAP in inhibiting executioner caspases and caspase 9 (Jaiswal et al., 254 
2015).  255 
Doxorubicin causes apoptosis in cardiomyocytes and cancer cells, can induce senescence, and 256 
appeared a reasonable choice to see if drug-triggering could be used to identify differences in 257 
apoptotic signals comparing qVICs and aVICs (Wang et al., 2004). For qVICs and aVICs there were 258 
similar changes in the genes involved in the earlier stages of the apoptotic signalling pathway, 259 
including increase in pro-apoptotic BID and decrease in anti-apoptotic BCL2 and DDIAS. Diseased 260 
VICs did not demonstrate a significantly more pro-apoptotic state than healthy VICs. This contrasts 261 
somewhat with previous reports looking at protein expression for BAX, BCL-2 and cleaved caspases 262 
in MMVD valves (Surachetpong et al., 2013). Furthermore, transcriptomic profiling of canine aVICs 263 
has identified several gene changes associated with down-regulation of apoptotic pathways and 264 
heightened senescence (Tan et al., 2019). 265 
While it was anticipated that doxorubicin treatment would induce more clear changes in gene 266 
expression comparing the two VIC populations, this may not have happened due to the greater 267 
importance of post-translational changes (Jager and Zwacka, 2010). This is particularly true in the 268 
case of caspases, as they require cleavage or dimerization to be activated (Plati et al., 2011). Further 269 
work is now needed to examine baseline protein expression in the two cell types, and after 270 
doxorubicin exposure, before the data presented here can be interpreted as convincing proof of 271 
apoptosis. Use of TUNEL staining, as a commonly used measure of apoptosis, would also be need to 272 
confirm and compliment the EH/AO findings 273 
The possible contribution of variance in cell phenotype also needs to be considered, such that cells 274 
even from diseased valves can be at varying stages of apoptosis, necrosis or senescence, and the 275 
summative gene expression (up or down) resulting in no change in the level of gene expression. This 276 
confounder was minimised to a certain extent in this study. Lastly, doxorubicin can also induce TGF-β 277 
signalling that can transform qVICs to aVICs in heart valves and fibroblasts to myofibroblasts in 278 
myocardium, and may have had a similar effect transitioning qVICs to aVICs (Tan et al., 2019). While 279 
we assessed changes in cell phenotype based on morphology we did not examine changes in ACTA2 280 
or TAGLN expression in the treated qVICs. Nevertheless, the time course experiments and the 281 
examination of cells using EH/AO suggested doxorubicin was having a differential effect on the 282 
aVICs.  283 
5. Conclusion 284 
It has previously been suggested that cells in MMVD valves are possibly in a pro-apoptotic state, but 285 
the gene expression shown here, and the temporal and spatial distribution of aVICs in normal and 286 
affected valves suggest arrested apoptosis might contribute to the appearance and survival of 287 
activated myofibroblasts in canine MMVD. Further work is now required to confirm if this is the case 288 
by examining expression of cleaved and activated proteins in activated myofibroblasts.   289 
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Figure Legends 295 
Figure. 1. Representative photomicrographs of alpha smooth muscle actin (αSMA+) staining in 296 
canine mitral valves at different stages of myxomatous degeneration. Upper part of each panel, 297 
αSMA (green) showing valve interstitial cell location, and lower part αSMA/DAPI (blue) showing the 298 
valve shape and extent of pathology. The intense staining (non-specific) at the far right each 299 
photomicrograph of each valve is the atrial myocardium. Bar =200μm. 300 
 301 
Figure 2. Representative photomicrographs of cultured REM134 canine mammary carcinoma cell 302 
line cells, normal valve interstitial cells (Normal VIC) and diseased valve interstitial cells (Diseased 303 
VIC) prior to and after 2mM doxorubicin hydrochloride treatment. For each cell type there is an 304 
increase in cell numbers but also an increase in the number of dead cells. Bar = 100μm. 305 
 306 
Figure 3. Representative immunofluorescent photomicrographs of ethidium homodimer and 307 
acridine orange staining illustrating live (L; green), dead (red) and apoptotic (green nucleus) cells in 308 
normal and diseased valve interstitial cell cultures at 0hrs and at 8hrs with or without 2mM 309 
doxorubicin hydrochloride treatment. Bar = 100μm. 310 
 311 
Figure 4. Difference in ΔCt between 0 hour and 8 hour for the genes CASP3, FAS, BID, BAX, BCL2, 312 
CASP8, DDIAS, XIAP and BIRC5 plotted for diseased (D) and healthy (N) VICs, both treated (2 mM 313 
doxorubicin)  (T – blue) and untreated (UT – green). An increase in the difference in ΔCt above 0 314 
suggests a decrease in gene expression at 8 hours compared to 0 hours. 315 
 316 
 317 
Gene Forward primer 5’-3’ 
Reverse primer 5'-3' 
Product 
length 
(bp) 
Tm 
(˚C) 
Reaction 
efficiency 
(%) 
Slope R2 
BCL-2 ACAACATCGCCCTGTGGAT 133 62 109.9 -3.105 0.96 
 
AGCCAGGAGAAGTCAAACAGA 
     
BAX CCTCTTCTACTTTGCCAGCA 93 61 103.7 -3.237 0.98 
 
AAGTCCAGTGTCCAGCCCAT 
     
BIRC5 ACTGGACAAAGAAAGAGCCAAG 84 62 96.7 -3.404 0.96 
 
ACTTTCTTTGCGGTCTCTTCG 
     
CASP3 TTCATTATTCAGGCCTGCCGAGG 83 59 91.6 -3.542 0.99 
 
TTCTGACAGGCCATGTCATCCTCA 
     
CASP8 ACAAGGGCATCATCTATGGCTCTGA 70 61 103.2 -3.247 0.99 
 
CCAGTGAAGTAAGAGGTCAGCTCAT 
     
DDIAS GAAACACTGGACCATGATGCA 122 62 102 -3.275 0.87 
 
TCTGAACCTTGTCCGTGTTG 
     
BID AGGACTACGACGATGAGCTG 150 59 94.4 -3.463 0.96 
 
TGTGATCCATCCTGTCCCCT 
     
XIAP GTGCTCAGAAAGACCATACACA 149 58 94.1 -3.473 0.99 
 
GCAAGGAATGAAAACCACAGC 
     
FAS AGATCGGGTAGGAACGTCAC 141 59 106.6 -3.173 0.8 
 
ACAGTGTGATTTACCCGCAT 
     
ACTA2  CGGCTACTCCTTTGTGACG 100 58 102.2 
  
 
CGTGGCCATCTCGTTCTC 
     
TAGLN  GACATGTTCCAGACCGTCGA 199 59 106.7 
  
 
CAATGACGTGCTTTCCCTCC 
     
Table 1. Reference and target gene forward and reverse primer sequences, product length, optimal 318 
annealing temperature and reaction efficiency. 319 
 320 
Gene Fold Change P-value 
BID 0.98 0.977 
FAS  1.22 0.722 
CASP3 0.91 0.883 
BAX 0.98 0.964 
CASP8 1.2 0.681 
BCL2 0.74 0.492 
BIRC5 1.58 0.631 
DDIAS 2.43 0.363 
XIAP 0.95 0.939 
 321 
Table 2. Fold change, with associated p-values, comparing baseline gene expression between normal 322 
and diseased VICs. 323 
 324 
Gene Diseased vs 
healthy p- 
value 
Treated vs 
untreated p- 
value 
Interaction Fold change 
healthy VIC 
(0 hour to 8 
hour treated) 
Fold change 
diseased VIC 
(0 hour to 8 
hour treated) 
CASP3 0.224 0.378 0.979 1.08 0.97 
FAS 0.105 0.144 0.214 1.01 0.52 
BID 0.960 0.016* 0.790 1.13 1.07 
BAX 0.678 0.952 0.154 1.02 0.84 
BCL2 0.413 0.003* 0.299 0.75 0.67 
CASP8 0.195 0.016* 0.015* 0.94 0.54 
DDIAS 0.197 <0.001* 0.390 0.37 0.25 
XIAP 0.413 0.113 0.965 0.85 0.74 
BIRC5 0.756 0.052 0.425 1.36 1.27 
 325 
Table 3. Mixed-model ANOVA comparison of gene changes in response to doxorubicin at 8 hours in 326 
normal and diseased VICs.*statistically significant p<0.05. 327 
 328 
Figure 1. 329 
 330 
Figure 2. 331 
 332 
 333 
 334 
 335 
 336 
Figure 3. 337 
 338 
Figure 4. 339 
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